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ABSTRACT
N-of-1 trials target actionable mutations, yet such approaches do not test 
genomically-informed therapies in patient tumor models prior to patient treatment. 
To address this, we developed patient-derived xenograft (PDX) models from fine 
needle aspiration (FNA) biopsies (FNA-PDX) obtained from primary pancreatic ductal 
adenocarcinoma (PDAC) at the time of diagnosis. Here, we characterize PDX models 
established from one primary and two metastatic sites of one patient. We identified 
an activating KRAS G12R mutation among other mutations in these models. In explant 
cells derived from these PDX tumor models with a KRAS G12R mutation, treatment 
with inhibitors of CDKs (including CDK9) reduced phosphorylation of a marker of 
CDK9 activity (phospho-RNAPII CTD Ser2/5) and reduced viability/growth of explant 
cells derived from PDAC PDX models. Similarly, a CDK inhibitor reduced phospho-
RNAPII CTD Ser2/5, increased apoptosis, and inhibited tumor growth in FNA-PDX and 
patient-matched metastatic-PDX models. In summary, PDX models can be constructed 
from FNA biopsies of PDAC which in turn can enable genomic characterization and 
identification of potential therapies.
INTRODUCTION
Precision medicine (using a patient’s unique 
genetic and molecular data to inform treatment, also 
known as personalized medicine) may present clinicians 
with opportunities to improve patient care. Ideally, data 
regarding a patient’s tumor could be used in a predictive 
manner to inform the clinician of the most appropriate 
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therapy. However, there are serious challenges in 
translating molecular and genetic data into clinical 
practice. Current clinical trials of targeted therapeutics 
focus on performance in a patient cohort and cannot 
evaluate multiple therapeutic options for individual 
patients. To advance precision medicine that benefits 
individuals, we must develop robust models to evaluate 
the efficacy of potential therapies while the patient is alive.
Patient-derived xenograft (PDX) models address 
this unmet need by allowing clinicians to evaluate and 
compare multiple therapies. The standard approach to 
construct PDX models relies on surgical specimens and 
is well characterized in pancreatic ductal adenocarcinoma 
(PDAC). [1,2] Such models recapitulate the heterogeneous 
tumor morphology, response to chemotherapeutics, and 
gene expression patterns observed in patient tumors. 
[1,3–9] Engrafting tumors in these models relies upon 
factors such as tumor type, cell number, murine host 
strain, protocol methodology, and tumor biology. [1,10–
12] In published research, the rates of engraftment and 
tumor growth range from 14 to 21 weeks. [1,4,12] In 
clinical practice, the short window between diagnosis and 
disease progression for aggressive malignancies limits 
the application of PDX models from surgical specimens 
as a method to evaluate individualized therapies. [13,14] 
While technically feasible, construction of PDX models 
with surgical specimens from aggressive malignancies 
is limited to patients with localized tumors that can be 
surgically removed. This is especially true for pancreatic 
cancer which is characterized by late presentation and only 
a minority (10-15%) of patients present with localized 
tumors that are amenable to up-front surgical resection.
One way to address this problem is to establish 
PDX models from patients with early-stage disease at the 
time of diagnosis. For many cancers, a tissue diagnosis 
is established by fine needle aspiration (FNA) biopsy. 
This specimen could be used to establish FNA-PDX 
models from early-stage disease. At our institution, 
patients undergo an endoscopic ultrasound (EUS) with 
FNA biopsy to establish a diagnosis of PDAC before 
the patient is considered for neoadjuvant therapy and 
resection. This biopsy method allows multiple quadrants 
within the primary tumor to be targeted for tumor cell 
acquisition. The resulting pooled specimen represents 
random sampling of tumor cells from the primary tumor 
microenvironment. After tissue diagnosis is established, 
all patients in our cohort are enrolled onto neoadjuvant 
chemoradiation protocols. Therefore, our clinical pathway 
does not allow us to obtain treatment naïve tumor tissue 
for genomic characterization or PDX engraftment at the 
time of surgical resection.
Unfortunately, FNA specimens derived from 
primary tumors such as PDAC contain a paucity of tumor 
cells mixed with host stromal cells. The FNA specimen 
therefore often contains too few tumor cells to perform 
genomic profiling. However, PDX tumors derived from 
FNA biopsies provide sufficient material for genomic 
characterization. [15] Using targeted sequencing, we 
observed that the mutational profile of FNA-PDX tumors 
matches that of models derived from patient-matched 
peritoneal and liver metastases. Genomic characterization 
of these models revealed a KRAS mutation. Increased 
RAS pathway signaling by oncogenic KRAS mutations 
has been implicated as a driver in PDAC; mutations in 
KRAS are found in over 90% of pancreatic tumors. [16,17] 
Direct and effective targeting of mutant KRAS in tumors 
has thus far not been achieved. [18,19] To circumvent 
this challenge, we previously set out to find the Achilles 
heel of cells with mutations in the RAS pathway. The 
principles of synthetic lethality allow us to treat a tumor 
with minimal toxicity to non-cancerous cells by exploiting 
vulnerabilities caused by oncogenic alterations. [20–23] 
Indeed, this approach has previously been utilized to 
discover synthetic lethal interactions in KRAS-mutant 
cells. [24] We devised an approach to identify compounds 
and experimental drugs that are synthetic lethal with 
increased RAS signaling caused by loss of the RAS-
GTPase activating protein (RAS-GAP) NF1. [25] One of 
our tool compounds identified in our synthetic lethality 
screen shares a target (cyclin dependent kinase 9, CDK9) 
with two drugs in clinical trials. [25–27] Here, we show 
that FNA-PDX and patient matched metastatic-PDX 
models with KRAS mutations are sensitive to inhibitors 
of CDK9.
This proof of concept study demonstrates that FNA-
PDX tumor models can be used to evaluate personalized 
therapies such as CDK inhibitors for rapidly progressing 
malignancies like pancreatic adenocarcinoma. There are 
several challenges for PDX-directed precision medicine. 
The models must be established during the clinical 
window for aggressive malignancies, they must capture 
the clones present within the primary tumor responsible 
for recurrence, and they must allow us to compare 
therapies before recurrence. Here, we describe an FNA-
PDX protocol that addresses these challenges.
RESULTS
FNA-PDX models are efficiently engrafted from 
FNA specimens at the time of diagnosis prior to 
planned neoadjuvant therapy
From December 2011 until May 2014, 34 patients 
were consented for FNA-PDX engraftment. 29 patient 
FNA specimens were acquired and engrafted into a 
subcutaneous flank pocket of a single NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) male mouse. Three patients had non-
PDAC histology on final cytopathologic diagnosis and 
two patients had metastatic disease diagnosed at the time 
of EUS resulting in 24 patient FNA specimens engrafted 
from patients with localized biopsy proven PDAC. The 
specimen was placed directly into a cryovial on ice. The 
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warm ischemia time, defined as the time from FNA biopsy 
until placement onto ice, was negligible. The median cold 
ischemia time (the time from biopsy until the time of 
mouse implantation) was 37 minutes. For patients who 
underwent subsequent surgery, tumor tissue was acquired 
from either primary tumors or metastatic sites for PDX 
engraftment. The clinical protocol and FNA-PDX program 
are illustrated in Figure 1.
To date, 9/24 (37.5%) FNA specimens have been 
successfully engrafted as PDX tumors. For patients who 
were discovered to have metastatic disease upon surgical 
exploration, tumor tissue was acquired and 10/10 (100%) 
of representative metastatic sites were successfully 
engrafted. Once engrafted, all but one FNA-PDX primary 
and metastatic-PDX models were successfully passaged 
up to the fifth (F5) passage. Once established, frozen PDX 
tumors could be thawed and engrafted for in vivo testing 
of therapeutic response.
FNA-PDX and patient matched metastatic-PDX 
tumor morphology and growth rates
We selected patient #008’s FNA-PDX as a proof of 
concept for model characterization. This patient is unique 
because metastatic disease developed during the time of 
FNA-PDX engraftment. Two metastatic sites of disease 
(peritoneal carcinomatosis and liver metastases) were 
biopsied and engrafted as metastatic M1 and M2 PDX 
models, respectively. This allowed us to characterize FNA 
and metastatic-derived PDX models concurrently.
The FNA-PDX tumor resembled the morphology, 
glandular formation, differentiation, and the desmoplastic 
stroma commonly seen in PDAC. We observed this in 
both the F0 (Figure 2A) and F4 (Figure 2B) passages. The 
morphologic heterogeneity between the FNA-PDX and 
the two metastatic models is depicted by H&E staining. 
The tumor contained mouse stromal cells (negative by 
human HLA immunohistochemical staining) recruited 
by the engrafted tumor cells (positive by human HLA 
immunohistochemical staining). The human tumor 
cells retained the expression of plectin-1, a putative 
PDAC biomarker (Figure 2A,B). [28] The RAS/MAPK 
signaling pathway was active, as evidenced by the 
immunohistochemical expression of the downstream 
effectors phosphorylated MEK and phosphorylated 
ERK1/2 (Figure 2A, 2B).
Tumor engraftment and growth characteristics of 
the FNA-PDX and patient-matched metastatic M1 and 
M2 models are shown in Figure 2C-E. The FNA-PDX F0 
tumor took nearly 18 weeks to reach 5 mm in diameter, 
while passaged F1-F4 tumors uniformly grew faster 
(Figure 2C). Interestingly, the passaged FNA-PDX tumors 
Figure 1: Clinical pathway for establishing FNA-PDX models at time of diagnosis of pancreatic ductal adenocarcinoma. 
Patients enrolled in this study undergo an EUS-FNA biopsy to establish a diagnosis of PDAC prior to consideration of neoadjuvant 
chemotherapy and resection. During this procedure, a pooled FNA specimen is obtained for engraftment into an NSG mouse. This F0 
FNA-PDX model is genomically characterized and passaged to further mice to enable evaluation of multiple therapies. Simultaneous to 
the development of the FNA-PDX model, patients with a diagnosis of PDAC in our cohort are enrolled onto neoadjuvant therapy protocols 
with subsequent resection of the tumor.
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growth rates were similar to the patient-matched passaged 
metastatic M1 (Figure 2D) and M2 (Figure 2E) models.
The FNA-PDX pipeline stably maintains 
primary tumor clones that resemble PDX tumors 
established from sites of metastases
We used a targeted next-generation sequencing 
(NGS) panel that consisted of 48 cancer genes in 
the F0-F5 passages of the patient #008 FNA-PDX 
model (Table 1, Figure 3). Variants detected were then 
confirmed by a SNaPshot genotyping assay (Table 1). 
Genomic characterization of an FNA biopsy is generally 
limited by the paucity of tumor cells. For this patient 
there was not enough FNA specimen available after 
the clinical diagnostic procedures to perform genomic 
characterization. Therefore, we characterized tissue 
obtained from the FNA-PDX model as a surrogate of 
Figure 2: FNA-PDX and metastatic-PDX tumor growth and morphology. A-B. Representative images of H&E staining 
and immunohistochemical expression of human HLA (a marker specific to cells of human origin), plectin-1 (a marker of PDAC cells), 
phosphorylated MEK1/2 and phosphorylated ERK1/2 (markers of RAS pathway activity) in FNA-PDX and metastatic-PDX tumors for 
passages F0 (A) and F4 (B). Scale bars: 200 (H&E, p-ERK) μm and 100 μm (HLA plectin-1, p-MEK). C-E. FNA-PDX and patient-
matched metastatic-PDX tumor morphology and growth rates of successive passaged tumors.
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Table 1: Summary of next-generation sequencing of 50 cancer genes from the initial F0 and late F4 passages of FNA-
PDX #008 (FNA) and patient-matched metastatic-PDX (M1/M2) models. Alleles that were detected but eliminated from 
NGS data due to read quality were subsequently validated with a SNaPshot genotyping approach. Italicized variants were 
detected at an allelic frequency <10%.
Sample Gene Nucleotide Change AA Change COSMIC ID NGS? SNaPshot?
FNA F0 KRAS c.34G>C G12R COSM518 Yes Yes
TP53 c.659A>G Y220C COSM10758 Yes* Yes
JAK3 c.2164G>A V722I COSM34213 No** Yes
FNA F1 KRAS c.34G>C G12R COSM518 Yes Yes
TP53 c.659A>G Y220C COSM10758 Yes Yes
JAK3 c.2164G>A V722I COSM34213 Yes* Yes
FNA F2 KRAS c.34G>C G12R COSM518 Yes Yes
TP53 c.659A>G Y220C COSM10758 Yes Yes
JAK3 c.2164G>A V722I COSM34213 Yes* Yes
EGFR c.2219_2220insCATCG I740_P741insHR Yes No
EGFR c.2236_2250delGAATTAAGAGAAGCA E746_A750delELREA COSM6225 Yes No
FNA F3 KRAS c.34G>C G12R COSM518 Yes Yes
TP53 c.659A>G Y220C COSM10758 Yes Yes
JAK3 c.2164G>A V722I COSM34213 Yes Yes
EGFR c.2219_2220insCATCG I740_P741insHR Yes No
EGFR c.2236_2250delGAATTAAGAGAAGCA E746_A750delELREA COSM6225 Yes No
FNA F4 KRAS c.34G>C G12R COSM518 Yes Yes
TP53 c.659A>G Y220C COSM10758 Yes Yes
JAK3 c.2164G>A V722I COSM34213 Yes Yes
FNA F5 KRAS c.34G>C G12R COSM518 Yes Yes
TP53 c.659A>G Y220C COSM10758 Yes Yes
JAK3 c.2164G>A V722I COSM34213 Yes Yes
EGFR c.2219_2220insCATCG I740_P741insHR Yes No
EGFR c.2236_2250delGAATTAAGAGAAGCA E746_A750delELREA COSM6225 Yes No
M1 F0 KRAS c.34G>C G12R COSM518 Yes n/a
TP53 c.659A>G Y220C COSM10758 Yes n/a
JAK3 c.2164G>A V722I COSM34213 Yes n/a
BRAF c.1405G>C G469R COSM455 Yes n/a
M1 F4 KRAS c.34G>C G12R COSM518 Yes n/a
TP53 c.659A>G Y220C COSM10758 Yes n/a
JAK3 c.2164G>A V722I COSM34213 Yes n/a
(Continued )
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Sample Gene Nucleotide Change AA Change COSMIC ID NGS? SNaPshot?
M2 F0 KRAS c.34G>C G12R COSM518 Yes n/a
TP53 c.659A>G Y220C COSM10758 Yes n/a
JAK3 c.2164G>A V722I COSM34213 Yes n/a
BRAF c.1405G>C G469R COSM455 Yes n/a
M2 F4 KRAS c.34G>C G12R COSM518 Yes n/a
TP53 c.659A>G Y220C COSM10758 Yes n/a
JAK3 c.2164G>A V722I COSM34213 Yes n/a
BRAF c.1405G>C G469R COSM455 Yes n/a
*Variant had coverage below 300x. **Amplicon drop-out.
Figure 3: Next-generation sequencing of passaged FNA-PDX models revealed shared alleles with metastatic sites. 
Unobserved tumors (dashed circles) with inferred alleles (grey text) based on sequencing of F0-F5 primary and F0 & F4 metastatic tumors 
(black filled circles). Mutations identified as unique to later passage PDX models from the primary tumor are present in early passage PDX 
models from metastatic sites. This suggests that passaging of FNA-PDX models selects for tumor cells that match the genetic profile of the 
metastatic tumors. *did not meet quality thresholds for NGS and were confirmed by SNaPshot genotyping. **amplicon drop-out by NGS, 
confirmed by SNaPshot.
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the primary tumor. In the FNA-PDX F0 and F1 passage, 
we identified three variants. One was a TP53 mutation 
(Y220C; COSM10758) in which inactivating mutations 
have been observed following KRAS activating mutations 
in PDACs. [29,30] The TP53 mutation had low coverage, 
however it was confirmed with a SNaPshot assay and 
Sanger sequencing. The other mutation was a KRAS 
mutation (G12R; COSM518) that has been frequently 
observed in PDACs. [31] This KRAS allele is an indicator 
of poor prognosis in PDACs. [32] A JAK3 mutation 
(V722I; COSM34213) was also observed in the F0 FNA-
PDX model. This mutation in JAK3 has not been reported 
in PDAC but has been observed in acute megakaryoblastic 
leukemia. [33,34] Due to a limited FNA biopsy sample 
size, sequencing of the primary tumor was impossible. 
Inferred mutations in the patient tumor in Figure 3 are 
labeled in grey text.
Sequencing the FNA-PDX F2-F5 passages indicated 
the presence of the same KRAS, TP53 and JAK3 mutations 
observed in passages F0 and F1. In passages F2, F3 
and F5, we also observed two EGFR mutations (I740_
P741insHR, E746_A750delELREA; COSM6225) that 
occurred at an allelic frequency below 10%. The JAK3 
mutation was not detected by NGS in the FNA F0 sample 
due to amplicon drop-out. EGFR mutations were not 
confirmed due to low allelic frequency.
Targeted NGS was also performed on the patient-
matched metastatic-PDX models. Sequencing of the 
M1 and M2 metastatic-PDX models strongly suggests 
that the KRAS, TP53 and JAK3 mutations existed in the 
primary pancreatic tumor, as the same KRAS, TP53, 
and JAK3 variants were observed in the FNA, M1, and 
M2 PDX models (Figure 3). Additionally, sequencing 
of the F0 passage of both metastases revealed a BRAF 
(G469R; COSM455) mutation. Co-mutation in BRAF 
and KRAS in PDAC has been reported by some groups 
while others have found that mutations in these two genes 
are mutually exclusive. [35–37] The observed BRAF 
mutation in the F0 passage of the peritoneal metastasis 
(M1) was not detectable in the F4 passage. In contrast, 
the BRAF mutation in the F0 from the liver metastasis 
(M2) was maintained through the F4 passage. There are 
two possibilities consistent with our data; that the variants 
present in the F0 FNA-PDX also existed in the primary 
tumor, or that they were independently acquired during 
engraftment of the F0 FNA-PDX as well as in the process 
of engraftment of the F0 M1/M2 metastatic-PDX models. 
We consider the former to be more likely, but do not have 
the data to distinguish these two possibilities.
Low passage explants from PDX models 
established in vitro retain the same markers as the 
tumor cells in vivo
To rapidly evaluate drug efficacy in tumor cells, 
we established explants in vitro from the #008 M2-PDX 
tumor (Figure 4A) and from xenograft tumors generated 
with cell cultures directly established in vitro from patient 
#008’s metastatic pancreatic tumors (M1, Supplementary 
Figure S1). We used polymerase chain reaction (PCR) 
with human and mouse specific primers to determine 
the species composition of the explants (Figure 4A, 
Supplementary Figure S1A). We confirmed human content 
by immunofluorescence with antibodies against human 
leukocyte antigens (HLAs) class I A, B, and C, which 
are expressed by most nucleated human cells (Figure 4B, 
Supplementary Figures S1B). [38] These methods indicated 
that the explants were entirely of human origin and not 
mouse stromal origin. Sanger sequencing confirmed that 
these cells maintained the KRAS G12R mutation observed 
in the M1/M2 tumors (Supplementary Figure S2).
CDK9 inhibition suppresses growth of primary 
and metastatic-PDX tumors in vitro and in vivo
We previously used high-throughput screens to 
identify drug targets for cancer cells in which increased 
RAS signaling due to loss of a RAS-GAP drives tumor 
formation. Using this approach we found that cells with 
increased RAS signaling are sensitive to inhibition of a 
cyclin dependent kinase that phosphorylates RNA Pol 
II CTD on Ser2. [25,39] One RNA Pol II CTD Ser2 
kinase in humans is CDK9 (the functional subunit of 
p-TEFb), for which there are two inhibitors in clinical 
trials (dinaciclib and SNS-032). We evaluated the 
effect of dinaciclib and SNS-032 on phosphorylation of 
RNA Pol II CTD Ser2/5 in explant cells derived from 
patient #008’s PDX models. The primary explants 
from our M1- and M2-PDX models exhibit RNA 
Pol II CTD phosphorylation at Ser2/5 that can be 
reduced by treatment with either dinaciclib or SNS-
032 (Figure 4C, 4D, Supplementary Figure S1C, S1D). 
Furthermore, dinaciclib and SNS-032 stopped the in 
vitro growth/reduced viability of explants derived from 
the PDX models established from metastatic tumors at 
concentrations that significantly decreased p-RNAPII 
CTD Ser2/5 (Figure 4C–4E, Supplementary Figure S1E-
S1G).
We then tested whether dinaciclib inhibited 
the growth of patient #008’s PDX tumors in vivo by 
implanting the FNA-PDX and the metastatic (M1-PDX) 
tumors in mice, and treating with dinaciclib or vehicle for 
four weeks (Figure 5). Dinaciclib treatment suppressed 
the growth of the FNA-PDX and the metastatic M1-PDX 
tumors (Figure 5A–5D) decreased phospho-RNAPII 
CTD Ser2/5 signal in the tumors, and altered tumor/
stromal morphology (Figure 5E–5H). Dinaciclib treatment 
increased apoptosis in FNA-PDX tumors as measured by 
caspase-3 cleavage (Figure 5I, 5J). These data suggest 
that cells with a KRAS G12R mutation may be vulnerable 
to CDK2 and/or 9 inhibition, targets shared by both 
dinaciclib and SNS-032.
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Figure 4: Explant cells generated from PDX models for rapid testing of targeted therapeutics are sensitive to CDK9 
inhibitors. A-B. PCR primers specific to human CHEK1 and mouse Chek1 were used to identify mouse and human content in PDX explant 
cells, using U87-MG cells as a human positive control and mouse genomic DNA as a mouse positive control. (A) Cells from a liver metastasis 
explant (M2) had human CHEK1 DNA but did not have mouse Chek1 DNA. (B) To validate this, α-Human HLA class 1 A, B, and C expression 
(a marker of cells of human and not mouse origin) were examined by immunofluorescence. All M2 explant cells evaluated were found to be 
α-Human HLA A, B and/or C positive. Human (H522) and mouse (ED1L) cell lines were used as controls. Scale bar: 20 μm. C. A KRAS 
mutant PDX explant treated for 24 h with the CDK9 inhibitors dinaciclib (10 nM and 200 nM) and SNS-032 (50 nM and 200 nM) has reduced 
Ser2/5 phosphorylation of the CTD of the large subunit of RNAPII. Scale bar: 20 μm. D. Box plots of the quantification of total fluorescent 
intensity per unit area of cells treated with dinaciclib and SNS-032 and stained for p-Ser2/5 RNAPII CTD. Data presented was collected in 
three independent experiments. E. Dinaciclib (IC50: 13 nM) and SNS-032 (IC50: 165 nM) inhibit the growth of explant cells during a 3 day 
treatment. Data presented is the average fluorescence and corresponding standard error of the mean for three independent experiments.
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Figure 5: Dinaciclib inhibits tumor growth in KRAS mutant FNA-PDX and metastatic-PDX models. A-D. Dinaciclib 
inhibits the growth of FNA-primary and patient-matched metastatic-PDX tumors in vivo. (A) FNA-PDX models established from the patient’s 
primary tumor were treated with 40 mg/kg dinaciclib (top) or vehicle (bottom) 3 times per week for 4 weeks when the tumor reached 62.5 
mm3. Tumors were excised. (B) Loess regression curve of the tumor growth of FNA-PDX models from (A) during treatment with vehicle 
(red) or dinaciclib (blue). 95% confidence intervals are indicated by the grey region. (C) PDX models established from a peritoneal metastasis 
(M1 from Figure 3) were treated with 40 mg/kg dinaciclib (top) or vehicle (bottom) and tumors excised after 4 weeks of treatment. (D) Loess 
regression curve from (C) during treatment with vehicle (circles) or dinaciclib (squares). 95% confidence intervals are indicated by the grey 
region. E-F. Representative H&E and p-RNAPII CTD Ser2/5 immunohistochemical staining of FNA-PDX tumor sections from vehicle treated 
mice. Tumors treated with dinaciclib exhibit reduced p-RNAPII CTD Ser2/5 as compared to the vehicle control. (G-H) Representative H&E 
and p-Ser2/5 RNAPII CTD immunohistochemical staining of metastatic-PDX tumor sections from dinaciclib treated mice. I-J. Representative 
cleaved caspase-3 immunohistochemical staining in FNA-PDX tumors from vehicle (I) and dinaciclib treated mice (J).
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DISCUSSION
We constructed PDAC PDX models from FNA 
biopsies. In the FNA-PDX tumor, we identified molecular 
lesions that predicted response to targeted therapies (CDK9 
inhibition) identified through high-throughput screens. 
CDK9 loss in yeast was previously found to be synthetic 
lethal with increased Ras pathway signaling resulting 
from loss of the RAS-GAP NF1. [25] We observed that 
KRAS mutant FNA-PDX and metastatic-PDX explant 
cells had phosphorylation of Ser2/5 of the large subunit of 
RNAPII, and phosphorylation was reduced with two CDK9 
inhibitors, dinaciclib and SNS-032. Dinaciclib, an inhibitor 
of CDKs 1/2/5/9, was previously evaluated as a CDK5 
inhibitor in PDAC PDX models from surgical specimens. 
[2] SNS-032 has been shown to be selective for CDKs 2/7/9 
at the effective concentration used in our study. [40] These 
inhibitors reduced the growth of PDX explant cells in vitro. 
We observed that dinaciclib inhibited tumor growth and 
induced cell death in both FNA-PDX and metastatic-PDX 
models. Furthermore, dinaciclib inhibited CDK9 in these 
PDX tumors as indicated by a reduction in phosphorylation 
of Ser2/5 of the large subunit of RNAPII. Taken together, 
these results suggest that dinaciclib’s effect on growth of the 
KRAS-mutant FNA and metastatic pancreatic PDX models 
is due to inhibition of CDK2 and/or CDK9.
One major challenge that limits PDX application to 
individualized treatments in PDAC is tissue acquisition. 
To date, most PDX protocols require surgery, even for 
localized tumors, to obtain enough tissue for engraftment. 
[41] However, only a minority of patients presenting 
with biopsy proven PDAC can be considered for up-front 
surgical resection. Many patients with localized tumors 
cannot be considered for surgical resection due to age, 
comorbidities and declining performance status. For 
aggressive cancers, such as pancreatic and lung cancer, 
patients often never undergo surgery before starting 
systemic treatment. Kim et al. established PDX models 
from surgically resected tumors in patients treated with 
neoadjuvant therapy. [9,42] However, in order for PDX 
models to be used to inform patient therapy, these models 
need to be established from primary tumor tissue before 
the patient’s tumor is subjected to either chemotherapy or 
chemoradiation therapy. One source of treatment-naïve 
tumor tissue is the FNA biopsy performed at diagnosis 
of PDAC. While FNA biopsies can establish a tissue 
diagnosis with excellent sensitivity and specificity there 
is often limited cellular material available for molecular 
diagnostic or research studies. In the present study, we 
demonstrated engraftment of EUS-FNA biopsies from 
treatment-naïve primary pancreatic tumors into FNA-PDX 
models, enabling characterization and testing of therapies.
A second major challenge to using PDX models 
to inform therapy in aggressive malignancies is the 
narrow window from the time of diagnosis to disease 
progression. For patients with localized PDAC who 
undergo neoadjuvant therapy or surgery, the median 
time to recurrence is 1 year and 80% recur in 2 years. 
[43,44] We demonstrate the establishment of FNA-PDX 
models within this window. While the patient is receiving 
standard therapies, FNA-PDX models allow molecular 
characterization and testing of therapeutics to inform 
treatment options at the time of disease recurrence.
Tumor heterogeneity complicates the use of 
genomic assays for personalized medicine. [45–47] 
To establish FNA-PDX models, we targeted multiple 
quadrants of the tumor during the FNA biopsy for spatially 
diverse sampling of tumor cells within the primary 
tumor. [48–50] We hypothesized that engraftment of this 
sample would select for the clinically relevant clone in 
the FNA-PDX model. Other groups have demonstrated 
genomic stability in PDX models. [51] The stability of the 
model is critical if a patient’s PDX model will be used to 
inform therapy or for drug stability. To address this issue, 
Tignanelli and Yeh and colleagues showed stability of 
mutational frequencies in late passaged colorectal cancer 
and pancreatic cancer PDX models. [51] We also observed 
that a PDX model established from an FNA biopsy was 
genetically stable between the F0 and F5 passages. 
The FNA-PDX model had genetic features that were 
observed in the metastatic-PDX models. This suggests 
that xenotransplantation of FNA-PDX tumors permits the 
growth of clones represented in the patient’s metastatic 
sites. It also suggests that PDX models generated from 
the FNA biopsy of the primary tumor closely represents 
the clones with metastatic and invasive potential. Our 
data show that the response of the FNA-PDX to targeted 
therapies is recapitulated in patient-matched PDX models 
established from a metastatic site. These results in the 
FNA-PDX model may also show activity at the time of 
recurrence in a metastatic setting.
In conclusion, we show that FNA-PDX and patient-
matched metastatic-PDX models with KRAS mutations 
are sensitive to CDK9 inhibitors. This work illustrates 
that FNA-PDX models present significant opportunities to 
evaluate personalized treatments before disease recurrence 
for aggressive and difficult-to-treat malignancies. We 
show that FNA-PDX models can first, be efficiently 
established during the clinical window for aggressive 
malignancies, second, capture the clones present within 
the primary tumor with metastatic potential, and third, 




Beginning in December of 2011, Velos protocol 
number D11129 (CPHS 23034/IACUC 11-01-05) protocol 
began accrual. At our institution, patients presenting with 
a pancreatic mass and without metastatic disease on cross 
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sectional imaging were considered for EUS/FNA biopsy to 
establish a tissue diagnosis prior to multidisciplinary review 
and consideration for Dartmouth-Hitchcock/Norris Cotton 
Cancer Center neoadjuvant therapy protocols. FNA-PDX 
protocol consent was obtained before the procedure. Once 
cytopathologic diagnosis was confirmed by on-site review 
a 2nd or 3rd pass/repeat EUS/FNA biopsy was obtained 
for tumor cell acquisition. Patient demographics, EUS 
findings, cytopathology acquisition numbers, procedure, 
and specimen acquisition times were recorded. The FNA 
specimen was placed immediately on ice.
FNA specimen was washed with ice-cold DMEM 
(Hyclone, South Logan, UT, USA) containing 1% 
penicillin/streptomycin (Hyclone), centrifuged at 2000rpm 
x 2 minutes and resuspended in 50 μL DMEM. We placed 
an 8-12 week old male NSG mouse under isoflurane 
anesthesia and opened a small pocket on its right flank. 
The entire pooled FNA specimen was transplanted to a 
single NSG mouse flank as a heterotopic implantation. 
Briefly, through a small flank incision we created a 
subcutaneous pocket wherein the FNA specimen was 
implanted surgically. Tumor progress was measured three 
times weekly until the tumor reached 10 mm2. This initial 
PDX tumor was designated F0 as described by Monsma 
et al, Malaney et al and others. [10,52,53] The tumor was 
then passaged to bilateral flanks of two subsequent mice. 
Passaged tumors and mice were designated F1-F7, and 
portions of tumor tissue were banked in 10% phosphate-
buffered formalin (Polysciences, Warrington, PA, USA) 
for paraffin embedding, liquid nitrogen, and RNAlater 
(Qiagen, Valencia, CA, USA). Tissue was also banked at 
-140°C in FBS with 10% DMSO for later use in in-vivo 
experiments. All mouse procedures followed Institutional 
Animal Care and Use Committee protocols. Mice were 
raised in the Transgenics and Genetic Constructs Resource 
at Dartmouth College.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded tissue (5 μm sections). After deparaffinization 
in xylene and rehydration in decreasing concentrations 
of EtOH, slides were boiled in Epitope Retrieval Buffer 
(Bethyl Lab Inc., Montgomery, TX, USA) for either 20 
minutes (HLA) or 30 minutes (plectin-1, p-MEK, p-RPB1 
CTD S2/5). Tissue permeabilization in 0.5% Triton-X 
100/1% TBS was followed by either a 0.3% peroxide 
block in methanol (plectin-1, p-MEK, p-RPB1 CTD 
S2/5) or a normal serum block (HLA). After avidin/biotin 
blocking (Vector Labs, Burlingame, CA, USA), slides 
were incubated with the primary antibody overnight at 4°C 
or 1 hour at RT (p-RPB1 CTD Ser 2/5). Primary antibody 
dilutions were: HLA Class 1 ABC (Acris Antibodies Inc, 
San Diego, CA; 5 μg/mL), plectin-1 [E398P] (Abcam, 
San Francisco, CA, USA; 1:1000) and phospho-MEK1/2 
Ser221(166F8) (Cell Signaling, Danvers, MA, USA; 
1:50), phospho-p44/42 MAPK (ERK1/2) Thr202/
Tyr204 (Cell Signaling, 1:300) p-RPB1 CTD Ser 2/5 
(Cell Signaling; 1:25-1:200). Appropriate controls were 
performed on tumor sections without primary antibody 
(data not shown).
Phospho-MAPK p44/42 antibody incubation was 
performed overnight. Plectin-1 and p-MEK primary 
antibody incubation was followed by a 30-minute 
incubation with the secondary antibody (RT, 1:200). 
The HLA secondary antibody incubation was preceded 
by a 10-minute peroxide block. Secondary staining for 
p-MAPK p44/42 and p-Rpb1 CTD Ser 2/5 was performed 
with SignalStain Boost Reagent, Rabbit (Cell Signaling). 
After a 30-minute incubation with the ABC reagent 
(Bethyl Lab Inc, all antibodies except p-MAPK p44/42 
and p-RPB CTD S2/5), slides were developed with DAB 
(BD Pharmingen, San Jose, CA, USA) and counterstained 
with hematoxylin/Scott’s bluing reagent. H&E, cleaved 
caspase-3, and p-RPB CTD S2/5 slides were evaluated by 
a GI pathologist.
DNA extraction, next generation sequencing, and 
SNaPshot assay
Genomic DNA was extracted using the Gentra 
PureGene Kit (Qiagen, Valencia, CA, USA). Samples 
were quantified by Quant-iTTM PicoGreen® dsDNA Assay 
Kit (Life Technologies, Grand Island, NY, USA) before 
next generation sequencing. Sample preparation and 
sequencing was performed by a CLIA-approved molecular 
pathology core facility. Libraries were generated using 
the llumina TruSeq Amplicon Cancer Panel that consists 
of 212 amplicons mapped in 48 genes. At least 250 ng 
of DNA was used for the hybridization of oligo probes 
through the targeted region of genomic DNA, followed 
by extension and ligation, resulting in the formation of 
products containing the targeted regions of interest flanked 
by sequences required for amplification. Indices and 
sequence adapters were added by PCR. Finally, libraries 
were purified, normalized (to ensure equal representation 
of each sample), pooled, and sequenced on the Illumina 
MiSeq system. The average cluster density was 1074.9 K/
mm2, with 91.92% of the clusters passing quality control 
filters. Approximately 97.7% of the clusters were ≥Q30 
(Phred quality score).
Base-calling and sequence alignment to hg19 
were performed using the MiSeq reporter software. VCF 
files were generated using the Somatic Variant Caller 
for the TruSeq Amplicon Cancer Panel. VCF files were 
then uploaded to VariantStudio v2.1.36, where variants 
were annotated, classified, and filtered for quality and 
significance. The initial step of the filtering process was to 
remove non-coding or low-quality variants (quality score 
<100). An additional filter was then applied to remove 
those that were present at less than 7.5% allelic frequency 
or were covered at less than 300x. Remaining variants were 
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individually interrogated using the UCSC Genome Browser 
GRCh37/hg19 assembly (http://genome.ucsc.edu).
In order to confirm the variants detected by NGS, 
we designed a genotyping panel using the SNaPshot 
technology. SNaPshot is a multiplex genotyping assay that 
consists of multiple steps, which includes a multiplexed 
exon specific PCR using unlabeled oligonucleotide primer 
sets and a multiplexed single-base primer extension using 
fluorescently labeled dideoxynucleotide triphosphate. For the 
PCR, we designed primers for the following genes: EGFR, 
KRAS,JAK3, and TP53. For the extension PCR, we designed 
a total of three primers for the point mutations and two for the 
INDEL. Samples were normalized to approximately 10 ng/μl 
and approximately 20 ng of gDNA was used for the reaction. 
All samples, and a positive control for each mutation were 
amplified with unlabeled primers for genes and subjected to 
a multiplexed extension primer reaction using the SNaPshot 
Ready Reaction Mix (Life Technologies). Capillary 
electrophoresis of PCR products was performed using the 
ABI 3500 Genetic Analyzer with POP-7TM polymer and 
50 cm capillary. The genotyping results were analyzed using 
















EGFR (c.2236_2250del15, forward): CTGACTGACTG 
ACTGACTGTCCCGTCGCTAT-CAAG








Establishing low passage in vitro cell cultures 
from PDX models
When tumors were passaged, a separate aliquot of 
tumor tissue was minced in DMEM (Hyclone) containing 
10% FBS (Hyclone) and 1% penicillin/streptomycin 
(Hyclone) and placed into a 6-well plate (Corning, 
Tewksbury, MA, USA) and cultured at 37°C in humidified 
5% CO2. Media was changed every three to four days. 
Once cells reached 60-70% confluence, cells were 
trypsinized with a 0.05% trypsin (Cellgro) solution. In an 
attempt to isolate tumor cells from contaminating mouse 
stromal cells in early passage cell cultures, we monitored 
the trypsin incubation step under the microscope for 
differential adherence of cell populations. Less adherent 
mouse stromal cells were washed with cold PBS, aspirated 
and discarded to enrich the remaining adherent tumor cell 
population which was subsequently replated in DMEM 
with 10% FBS at 1-1.56 cells per 175cm2 flask. Early 
passage cell cultures were tested for mycoplasma, HIV 
and hepatitis B and C tested prior to in vitro studies.
Cell lines
Cell lines used as controls were obtained from the 
American Type Culture Collection (H522, U87-MG) or 
were a kind gift from Dr. Ethan Dmitrovsky (ED1L). Cells 
were cultured in RPMI 1640 (Corning, H522/ED1L) or 
DMEM (Corning, U87-MG) with 10% fetal bovine serum 
(Atlanta Biologicals, Flowery Branch, GA, USA). Cell 
lines were maintained at 37°C in humidified 5% CO2.
Immunofluorescence
Tumor explants were cultured on poly-D-lysine 
coated coverslips (Neuvitro Corporation, El Monte, 
CA, USA) and treated with dinaciclib (Izen Biosciences 
Pvt Ltd, Hyderabad, India) or SNS-032 (Selleckchem, 
Houston, TX, USA) for 24 hours. Cells were fixed in 3.7% 
formaldehyde (Fisher Scientific, Pittsburgh, PA, USA) in 
PBS (Corning) and blocked with IF buffer (2%[v/v] goat 
serum, 0.2%[v/v] Triton X-100 and 0.05%[w/v] sodium 
azide in PBS) at RT. Ser2/5 phosphorylation of the CTD 
of the large subunit of RNAPII was labeled using 1:400 
rabbit anti-phospho-Rpb1 CTD Ser 2/5 #4735 at room 
temperature for one hour (Cell Signaling) and 1:800 goat 
anti-rabbit F(ab’)2 DyLight 594 at room temperature for 
1 hour (Thermo Scientific, Waltham, MA, USA) diluted 
in IF buffer. Images were acquired with a Zeiss Imager 
Z1 wide-field microscope equipped with a 40x 1.3 NA 
EC Plan-NEOFLUAR objective and Zeiss Axiovision 
software.
Immunofluorescence images were composited/
measured using Fiji. [54] We used previously described 
methods to quantify fluorescent intensity. [55,56] Each 
measured region was defined with DAPI channel. The 
same size region was measured next to the cell for the 
background reading. Fluorescence intensity measurements 
were performed on cells stained for p-RPB CTD Ser2/5.
For comparisons between cells, we calculated corrected 
total fluorescence (CTCF) for each cell, which is the 
integrated density of cell minus area of selected cell times 
mean fluorescence of background readings for that cell. 
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We divided the value by the area of each cell to correct 
for cell size. This value was averaged over 100 cells for 
each of 3 replicates. All data are accessible via a publically 
available repository (doi: 10.5281/zenodo.34430). [57]
Characterization of explant cell lines
Tumor explants were cultured on poly-D-lysine 
coated coverslips (Neuvitro Corporation) and allowed to 
adhere overnight. Cells were fixed in 3.7% formaldehyde 
and blocked with IF buffer at RT. Cells of human origin 
were labeled using 1:200 rat anti-human HLA Class I ABC 
#SM2012P for one hour at RT (Acris Antibodies) and 1:100 
goat anti-rat FITC for one hour at RT (Sigma-Aldrich, St. 
Louis, MO, USA) diluted in IF buffer. Images were acquired 
with a Zeiss Imager Z1 wide-field microscope equipped 
with a 40x 1.3 NA EC Plan-NEOFLUAR objective. Images 
were processed and composited with Fiji. [54]
PCR was performed using primers directed towards 
mouse Chek1, human CHK1 (introns 3 and 6) and human 
KRAS. Species specific Chek1/CHK1 primers were used 
to confirm that the PDX-derived explant cells were of 
human origin. DNA extraction was performed in lysis 
buffer (0.45% Nonidet P40 [Roche, Nutley, NJ, USA], 
1X ThermoPol Taq buffer (New England Biolabs, Ipwich, 
MA, USA), and 100 μg/mL proteinase K [Roche]) at 
55°C. Amplification was performed in a 20 μL reaction 
volume including 1 μL DNA extract, 0.5 μM forward 
and reverse primer mixture, 200 μM dNTPs, 0.1 unit 
Taq DNA Polymerase (New England Biolabs), 2 μL 10X 
Standard Taq Buffer (New England Biolabs), and 15 μL 
nuclease-free water. The thermocycler protocol was as 
follows: 1. (94°C, 2 minutes), 2. (94°C, 15 seconds), 3. 
(58°C (CHEK1) or 52°C (KRAS), 30 seconds), 4. (72°C, 
1 minute, 5. (72°C, 10 minutes), with steps 2-4 repeated 
for 30-40 cycles. Amplified DNA and a 100 kb ladder was 
run on a 1.5% TBE-agar gel with ethidium bromide for 
40 minutes at 100 V and visualized with UV light. Sanger 
sequencing of KRAS was performed by the Dartmouth 
College Molecular Biology core facility using 5 pmol 
KRAS reverse primer and 20ng KRAS PCR product. 





Human CHEK1, intron 3:
Forward: 5’-atgacgccttttgccaccta-3’,
Reverse: 5’-cacccctgccatgagttgat-3’






Response to drugs in vitro
To perform drug sensitivity assays, cells were 
plated to 96-well plates at a concentration of 5000 cells/
well. After overnight incubation, medium was removed 
and replaced with 100 μL of medium containing 0-2000 
nM CDK9 inhibitor and DMSO (to normalize DMSO 
concentrations) was added. Cells were incubated for 3 days 
with a final 3-hour incubation in 5% AlamarBlue (Thermo 
Scientific). The plate was scanned at an Ex/Em of 544/590 
nm, and fluorescence was normalized to vehicle control 
wells. Dose-response curves and IC50s were calculated 
with the Prism 6 software package (GraphPad, San Diego, 
CA, USA) by performing a 4-parameter logistic regression 
with outlier exclusion analysis.
Response to drugs in vivo
FNA-PDX and metastatic-PDX models were 
established as described above. Mice were assigned 
to vehicle (20% hydroxpropyl-β-cyclodextrin, Sigma-
Aldrich) or dinaciclib treatment arms ensuring that both 
groups had an equal distribution of tumor sizes. Treatment 
was initiated when tumors reached approximately 62.5 
mm3. Mice were weighed prior to treatment and treated 
3 times weekly i.p. with 40 mg/kg dinaciclib in 20% 
hydroxypropyl-β-cyclodextrin or an equivalent amount of 
vehicle for 4 weeks. Mouse weight and tumor dimensions 
were measured prior to every treatment and volumes were 
calculated using the following formula:
Volume = ½ (L x W2)
Statistical methods for data analyses
Box plots were constructed using ggplot2 and the 
R programming language. [59,60] Tumor volumes over 
time were modeled using LOESS regression in R. [59] 
This technique models tumor volume over time using local 
measurements. 95% confidence intervals (grey regions) 
were calculated using the T approximation. All data are 
accessible via publically available repository (http://
dx.doi.org/10.5281/zenodo.34430). [57]
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